Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis.
Robinson AP, Zhang JZ, Titus HE, Karl M, Merzliakov M, Dorfman AR, Karlik S, Stewart MG, Watt RK, Facer BD, Facer JD, Christian ND, Ho KS, Hotchkin MT, Mortenson MG, Miller RH, Miller SD. Robinson AP, et al. Among authors: ho ks. Sci Rep. 2020 Feb 11;10(1):1936. doi: 10.1038/s41598-020-58709-w. Sci Rep. 2020. PMID: 32041968 Free PMC article.
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.
Vucic S, Kiernan MC, Menon P, Huynh W, Rynders A, Ho KS, Glanzman R, Hotchkin MT. Vucic S, et al. Among authors: ho ks. BMJ Open. 2021 Jan 11;11(1):e041479. doi: 10.1136/bmjopen-2020-041479. BMJ Open. 2021. PMID: 33431491 Free PMC article.
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Vucic S, Menon P, Huynh W, Mahoney C, Ho KS, Hartford A, Rynders A, Evan J, Evan J, Ligozio S, Glanzman R, Hotchkin MT, Kiernan MC. Vucic S, et al. Among authors: ho ks. EClinicalMedicine. 2023 Jun 8;60:102036. doi: 10.1016/j.eclinm.2023.102036. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396808 Free PMC article.
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: ho ks. J Nanobiotechnology. 2023 Dec 13;21(1):478. doi: 10.1186/s12951-023-02236-z. J Nanobiotechnology. 2023. PMID: 38087362 Free PMC article. Clinical Trial.
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: ho ks. J Nanobiotechnology. 2024 Jan 3;22(1):16. doi: 10.1186/s12951-023-02269-4. J Nanobiotechnology. 2024. PMID: 38167088 Free PMC article. No abstract available.
Protein Corona Composition of Gold Nanocatalysts.
Ashkarran AA, Tadjiki S, Lin Z, Hilsen K, Ghazali N, Krikor S, Sharifi S, Asgari M, Hotchkin M, Dorfman A, Ho KS, Mahmoudi M. Ashkarran AA, et al. Among authors: ho ks. ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):1169-1177. doi: 10.1021/acsptsci.4c00028. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633595
198 results